Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDL Diagnostics ABFRA:80R -2.54%53 Equity-to-Asset is 0.85 as of Jun. 2026, which is 10% below its 10-year median of 0.94. GuruFocus rates FRA:80R with a GF Score™ of 53/100 and a GF Value™ of €0.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, IDL Diagnostics AB ranks better than 90.52% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IDL Diagnostics AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €13.53 Mil. IDL Diagnostics AB's Total Assets for the quarter that ended in Jun. 2026 was €15.97 Mil.
Therefore, IDL Diagnostics AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.85.
The historical rank and industry rank for IDL Diagnostics AB's Equity-to-Asset or its related term are showing as below:
FRA:80R'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.84 Med: 0.94 Max: 0.97
Current: 0.85
During the past 13 years, the highest Equity to Asset Ratio of IDL Diagnostics AB was 0.97. The lowest was 0.84. And the median was 0.94.
FRA:80R's Equity-to-Asset is ranked better than 90.52% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs FRA:80R: 0.85
IDL Diagnostics AB (FRA:80R) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
IDL Diagnostics AB Equity-to-Asset Related Terms
IDL Diagnostics AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:80R vs TMO, DHR, NTRA: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
IDL Diagnostics AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (FRA:80R) has a Equity-to-Asset of 0.85 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IDL Diagnostics AB and its competitors. This is 10% below median its historical median of 0.94. Over the past decade, IDL Diagnostics AB's Equity-to-Asset has ranged from 0.84 to 0.97. According to the industry distribution chart, IDL Diagnostics AB ranks #20 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 9.5%.
Is IDL Diagnostics AB's Equity-to-Asset too high?
IDL Diagnostics AB's current Equity-to-Asset of 0.85 is 10% below median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 0.97. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. IDL Diagnostics AB's value of 0.85 is 44.1% above this industry median. Based on the distribution chart, IDL Diagnostics AB ranks #20 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDL Diagnostics AB has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #20 out of 211 companies for Equity-to-Asset. This places IDL Diagnostics AB in the top 10% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.59. IDL Diagnostics AB's value of 0.85 is 44.1% above this benchmark. Historically, IDL Diagnostics AB's own Equity-to-Asset has ranged from 0.84 to 0.97 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.59, IDL Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDL Diagnostics AB's current Equity-to-Asset of 0.85 is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on IDL Diagnostics AB and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDL Diagnostics AB's current Equity-to-Asset is 0.85, which is 10% below median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (FRA:80R) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.03, compared to a current price of €0.02 — trading 23.3% below its estimated fair value. The current Equity-to-Asset is 0.85, which is 10% below median its 10-year median of 0.94 and 44.1% above the Medical Diagnostics & Research industry median of 0.59. IDL Diagnostics AB's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For IDL Diagnostics AB (FRA:80R), the current Equity-to-Asset is 0.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (FRA:80R) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of €0.02 is trading 23.3% below its estimated GF Value™ of €0.03.
GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.
Key valuation signals for FRA:80R:
Equity-to-Asset: 0.85 (10% below median its 10-year median of 0.94)
GF Value™: €0.03 vs. price of €0.02 (23.3% below fair value)
Industry Position: 44.1% above the Medical Diagnostics & Research median (#20 of 211)
No single metric tells the full story. See the FRA:80R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
53GF Score
Get the complete analysis for FRA:80R
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:80R has been successfully added to your 
